Kite Pharma (Kite Pharma) Additional Paid-In Capital : $1,336.44 Mil(As of Jun. 2017)

View and export this data going back to 2014. Start your Free Trial

What is Kite Pharma Additional Paid-In Capital?

Kite Pharma's quarterly additional paid-in capital increased from Dec. 2016 ($855.56 Mil) to Mar. 2017 ($1,297.85 Mil) and increased from Mar. 2017 ($1,297.85 Mil) to Jun. 2017 ($1,336.44 Mil).

Kite Pharma's annual additional paid-in capital increased from Dec. 2014 ($420.85 Mil) to Dec. 2015 ($775.59 Mil) and increased from Dec. 2015 ($775.59 Mil) to Dec. 2016 ($855.56 Mil).

Kite Pharma Additional Paid-In Capital Historical Data

The historical data trend for Kite Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kite Pharma Additional Paid-In Capital Chart

Kite Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Additional Paid-In Capital

0.07

36.99

420.85

775.59

855.56

Kite Pharma Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
Additional Paid-In Capital	Get a 7-Day Free Trial														812.49	835.42	855.56	1,297.85	1,336.44

Kite Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Kite Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kite Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kite Pharma (Kite Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kite Pharma Inc (NAS:KITE) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.kitepharma.com

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.

Executives

Jonathan M Peacock	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David Bonderman	director	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Franz B Humer	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Shawn Tomasello	officer: Chief Commercial Officer	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Farah Champsi	director	ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Helen Susan Kim	officer: EVP, Business Development	3832 BAY CENTER PLACE, HAYWARD CA 94545
Timothy L. Moore	officer: EVP, Technical Operations	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Ran Nussbaum	director	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Cynthia M Butitta	officer: Chief Operating Officer	3165 PORTER DRIVE, PALO ALTO CA 94304
Owen N. Witte	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
David D Chang	officer: EVP, R&D, Chief Medical Off.	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joshua A Kazam	director	689 5TH AVENUE, 12TH FLOOR, NEW YORK NY 10022
Arie Belldegrun	director, officer: Chairman, President and CEO	UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Margo R Roberts	officer: Chief Scientific Officer	2225 COLORADO AVENUE, SANTA MONICA CA 90404

Kite Pharma (Kite Pharma) Headlines

From GuruFocus

Halvorsen Increases Kite Pharma as Interest in Health Care Remains High

By Holly LaFon Holly LaFon • 03-01-2016

Mario Gabelli Exits Kite Pharma, Trims Time Warner

By Tiziano Frateschi Tiziano Frateschi • 02-07-2018

Andreas Halvorsen Nearly Quadruples Stake in Kite Pharma

By David Goodloe David Goodloe • 10-06-2015

Mario Gabelli's Top 5 New Buys for the 3rd Quarter

By Sydnee Gatewood Sydnee Gatewood • 11-03-2017

Multiple Companies Achieve Yearly Highs

By yifan900 yifan900 • 10-03-2017